Table 1.

Overexpressed genes in well-differentiated and dedifferentiated liposarcoma compared with normal fat

GeneTitleFold change
(A) Well-differentiated liposarcoma versus normal fat gene list
    ZIC1Zic family member 137.2
    TOP2ATopoisomerase (DNA) II α 170 kDa32.4
    RRM2Ribonucleotide reductase M2 polypeptide18.1
    FOXD1Forkhead box D115.5
    GAS41Glioma-amplified sequence 4113.7
    CDK4Cyclin-dependent kinase 411.6
    MDM2MDM2, p53 binding protein10.2
    CDKN2ACyclin-dependent kinase inhibitor 2A (p16)9.0
    HCAP-GChromosome condensation protein G8.2
    IGF-IIInsulin-like growth factor II7.0
    SASSarcoma-amplified sequence6.8
    ARHGAP4Rho GTPase-activating protein 45.7
    TYMSThymidylate synthetase5.3
    MADL1MAD2 mitotic arrest deficient-like3.4
    OS4Conserved gene amplified in osteosarcoma3.3
    RACGAP1Rac GTPase activating protein 13.3
    RBL1Retinoblastoma-like 1 (p107)2.4
    RAD17RAD17 homologue, mitotic checkpoint2.4
    FUBP1Far upstream element (FUSE) binding protein 12.3
    BRCA2Breast cancer 2, early onset2.3
    MARKSMyristoylated alanine-rich protein kinase C substrate2.2
    IRS4Insulin receptor substrate 42.2
    CDC2Cell division cycle 2, G1-S and G2-M2.2
    UBE2BUbiquitin-conjugating enzyme E2B (RAD6 homologue)1.9
    RAD1RAD1 homologue, DNA damage response1.7
(B) Dedifferentiated liposarcoma versus normal fat gene list
    TOP2ATopoisomerase (DNA) II α 170 kDa103.2
    RRM2Ribonucleotide reductase M2 polypeptide38.5
    HECHighly expressed in cancer35.7
    ZIC1Zic family member 1 (odd-paired homologue, Dros.)35.5
    TROTrophinin28.3
    CDC2Cell division cycle 2, G1-S and G2-M19.9
    FOXD1Forkhead box D117.9
    HCAP-GChromosome condensation protein G17.2
    CDK4Cyclin-dependent kinase 414.0
    MELKMaternal embryonic leucine zipper kinase13.3
    CDC20CDC20 cell division cycle 20 homologue, spindle9.9
    MDM2Mdm2, p53 binding protein9.6
    TYMSThymidylate synthetase9.2
    CDKN2ACyclin-dependent kinase inhibitor 2A (p16)7.7
    CKS2CDC28 protein kinase regulatory subunit 27.5
    BUB1BBUB1 budding uninhibited by benzimidazoles 1 homologue β7.0
    MAD2L1MAD2 mitotic arrest deficient-like 16.3
    RACGAP1Rac GTPase-activating protein 16.1
    SASSarcoma-amplified sequence5.7
    CDH11Cadherin 11, type 2, OB-cadherin (osteoblast)5.2
    RRM2Ribonucleotide reductase M2 polypeptide5.2
    SOX4Sex-determining region Y–box 44.7
    CCNB2Cyclin B24.3
    SMOSmoothened homologue (Drosophila)3.4
    TCF3Transcription factor 33.4
    CCNE2Cyclin E23.2
    BAXBCL2-associated X protein3.2
    SSX2IPSynovial sarcoma, X breakpoint 2 interacting protein3.1
    CDKN3Cyclin-dependent kinase inhibitor 3 (CDK2-assoc dual specificity phosphatase)2.9
    UBE2CUbiquitin-conjugating enzyme E2C2.9
    GLI2GLI-Kruppel family member GLI22.8
    RBL1Retinoblastoma-like 1 (p107)2.8
    CKS1BCDC28 protein kinase regulatory subunit 1B2.8
    MARKSMyristoylated alanine-rich protein kinase C substrate2.8
    CCNB1Cyclin B12.8
    CDC7CDC7 cell division cycle 7, G1-S transition of mitotic cell cycle2.7
    FUBP1FUSE binding protein 12.7
    CALRCalreticulin2.6
    PLODProcollagen-lysine, 2-oxoglutarate 5-dioxygenase2.5
    CDC25BCell division cycle 25B2.5
    RFC4Replication factor C (activator 1) 4, 37 kDa, DNA replication2.4
    CHEK1CHK1 checkpoint homologue, DNA damage response2.0
  • NOTE: A, selected overexpressed genes from 251 genes that were differentially expressed with a FDR of <0.005, comparing the mean log gene expression levels in eight pure well-differentiated liposarcoma samples (no dedifferentiated component in sample or elsewhere in patient's tumor) to the mean gene log expression levels from nine normal fat tissue samples. B, selected overexpressed genes from the 130 genes that were differentially expressed with a FDR of <1 × 10−7 and >2-fold change, comparing the mean log gene expression levels of 20 pure dedifferentiated liposarcoma samples to those from nine normal fat tissue samples.